Anika Therapeutics (ANIK) Payables (2010 - 2026)

Anika Therapeutics (ANIK) has 17 years of Payables data on file, last reported at $6.3 million in Q1 2026.

• Payables for Q1 2026 came in at $6.3 million, up 20.13% year-over-year; the trailing twelve-month figure through Mar 2026 was $6.3 million (up 20.13% YoY), and the FY2025 annual result was $6.0 million, up 7.55% from the prior year.
• Payables grew to $6.3 million in Q1 2026 per ANIK's latest filing, from $6.0 million in the prior quarter.
• Over five years, Payables peaked at $10.0 million in Q1 2024 and troughed at $4.7 million in Q3 2025.
• A 5-year average of $7.3 million and a median of $7.4 million in 2022 frame the typical range for Payables.
• The sharpest annual moves came in 2024 and 2025: Payables climbed 25.81% in 2024, then tumbled 52.26% in 2025.
• A 5-year view of Payables shows it stood at $9.1 million in 2022, then plunged by 31.74% to $6.2 million in 2023, then dropped by 9.32% to $5.6 million in 2024, then climbed by 7.55% to $6.0 million in 2025, then advanced by 4.93% to $6.3 million in 2026.
• Business Quant data shows ANIK's Payables at $6.3 million in Q1 2026, $6.0 million in Q4 2025, and $4.7 million in Q3 2025.